Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Gefitinib (ZD1839, Iressa) is a low-molecular-weight EGFR ty...
| Class:Id | Summation:1181169 |
|---|---|
| _displayName | Gefitinib (ZD1839, Iressa) is a low-molecular-weight EGFR ty... |
| _timestamp | 2011-01-28 18:04:44 |
| created | [InstanceEdit:1181168] Orlic-Milacic, Marija, 2011-01-28 |
| literatureReference | [LiteratureReference:1169414] Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity [LiteratureReference:1181162] ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy |
| text | Gefitinib (ZD1839, Iressa) is a low-molecular-weight EGFR tyrosine kinase inhibitor (TKI) from the anilinoquinazoline class of TKIs, developed by AstraZeneca Pharmaceuticals. Gefitinib selectively inhibits EGFR-stimulated tumor cell growth and blocks EGFR autophosphorylation in tumor cells by competitive inhibition of ATP binding to kinase domain of EGFR (Wakeling et al. 2002, Yun et al. 2007). |
| (summation) | [ChemicalDrug:1169429] Gefitinib [cytosol] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Gefitinib (ZD1839, Iressa) is a low-molecular-weight EGFR ty... (1181169)
